Last reviewed · How we verify
NCT06775288
Hypoglycemia Prevention and Awareness Program
NA trial testing Hypoglycemia prevention and awareness program (HypoPAP) in Diabetes in 62 participants. Participants enrolled and being followed up; not accepting new ones.
15 December 2024
Quick facts
| Lead sponsor | Merve DerviAYoAYlu |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 62 |
| Start date | 1 November 2024 |
| Primary completion | 15 December 2024 |
| Estimated completion | 15 April 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Hypoglycemia prevention and awareness program (HypoPAP)
Conditions studied
- Diabetes — all drugs for Diabetes →
- Hypocalcemia — all drugs for Hypocalcemia →
- Telehealth — all drugs for Telehealth →
- Nursing Care — all drugs for Nursing Care →
Sponsor
Merve DerviAYoAYlu
Who can join
18 and older, any sex, with Diabetes or Hypocalcemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this project is to examine the effects of the Hypoglycemia Prevention and Awareness Program (HypoPAP) on patient outcomes, including metabolic, psychological, social, and economic parameters, in individuals with type 2 diabetes and impaired hypoglycemia awareness. Through the interventions provided to participants, the study aims to achieve the following improvements: * Physiological parameters: Enhanced glycemic control, reduced hypoglycemia frequency, improved hypoglycemia awareness, and optimized HbA1c levels. * Psychological parameters: Reduced fear of hypoglycemia, increased hypoglycemic confidence, and improved attitudes toward hypoglycemia management. * Social parameters: Decreased social withdrawal due to fear of hypoglycemia, as assessed through relevant items in validated scales. * Economic parameters: Reduced frequency of hospitalizations and emergency department visits. Overall, the program seeks to enhance participants' ability to prevent and manage hypoglycemia, thereby improving their overall well-being.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06775288
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06775288 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Merve DerviAYoAYlu
- Last refreshed: 15 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06775288.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing